Selective glucocorticoid receptor modulators (SGRMs) delay castrate-resistant prostate cancer growth

Increased glucocorticoid receptor (GR) expression and activity following androgen blockade can contribute to castration-resistant prostate cancer (CRPC) progression. Therefore, we hypothesized that GR antagonism will have therapeutic benefit in CRPC. However, the FDA-approved nonselective, steroidal...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Cancer Ther
Päätekijät: Kach, Jacob, Long, Tiha M., Selman, Phillip, Tonsing-Carter, Eva Y., Bacalao, Maria A., Lastra, Ricardo R., de Wet, Larischa, Comiskey, Shane, Gillard, Marc, VanOpstall, Calvin, West, Diana C., Chan, Wen-Ching, Griend, Donald Vander, Conzen, Suzanne D., Szmulewitz, Russell Z.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5544558/
https://ncbi.nlm.nih.gov/pubmed/28428441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0923
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia